Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLAIRIA-1
2025-524040-35-00Phase 3Authorised
- Sponsor
- Generate Biomedicines
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing GB-0895 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Annualized asthma exacerbation rate over 52 weeks. Planned start Jun 2026; status: authorised.
02
Drugs
GB-0895
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-524040-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524040-35-00.